Form 4: Regeneron Director Exercises, Sells Stock Under 10b5-1 Plan

Regeneron Pharmaceuticals Director Bonnie L. Bassler exercised stock options and sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Summary

• Bonnie L. Bassler, a Director at Regeneron Pharmaceuticals, Inc. (REGN), executed transactions on November 20, 2025.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan, which was adopted on May 2, 2025.
• Bassler acquired 760 shares of Regeneron common stock by exercising non-qualified stock options at a price of $371.4 per share.
• Concurrently, Bassler sold 760 shares of common stock at a price of $750 per share.
• Following these reported transactions, Bassler directly holds 1,548 shares of common stock and 756 non-qualified stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and the sale of an equal number of shares under a pre-arranged 10b5-1 plan. This is a common practice for executives managing their equity compensation and does not necessarily indicate a change in sentiment towards the company's prospects. The profit realized by the insider from the exercise and sale is notable.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planning and reducing the perception of opportunistic insider trading.
• The sale price of $750 per share significantly exceeds the exercise price of $371.4 per share, resulting in a profitable transaction for the insider.

Negatives

• An insider selling shares, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it reduces their direct equity exposure.

Industry Context

This filing reports a routine insider transaction by a director, which is a common occurrence for executives managing their equity compensation. It does not provide information directly related to broader industry trends or competitive landscape, but rather reflects an individual's personal financial planning.

Related Party Transactions

• The reported transactions involve a director of Regeneron Pharmaceuticals, Inc. exercising stock options and selling common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, could be interpreted by some as a reduction in insider confidence, though the pre-planned nature mitigates this concern. The transaction itself does not directly impact the company's operational performance or financial health.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction.

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction by a director, involving the exercise of stock options and the subsequent sale of an equivalent number of shares. Such transactions are common for executive compensation and personal financial planning, especially when executed under a Rule 10b5-1 plan, which mitigates concerns about opportunistic trading. The filing itself does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's fundamentals rather than this routine insider disclosure.

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Transaction, Stock Option Exercise, Stock Sale, Bonnie L. Bassler, 10b5-1 Plan, Director Transaction